Full-Time

Senior Director, Clinical Science

Clinical Development

Posted on 8/22/2026

Revolution Medicines

Revolution Medicines

1,001-5,000 employees

Clinical-stage oncology company developing RAS inhibitors

Compensation Overview

$244k - $305k/yr

+ Equity awards

Redwood City, CA, USA

Hybrid

The posting is hybrid; the displayed salary range is for onsite work at the Redwood City headquarters and is adjusted for the candidate's local market.

PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Revolution Medicines

See people who can refer or advise you

Requirements
  • A PhD, PharmD, or equivalent is required.
  • A minimum of 10+ years of experience in clinical development is required; pharmaceutical research and development experience outside clinical development may be considered based on transferable skills and responsibilities.
  • Extensive experience applying data analysis, interpretation, and clinical relevance principles and techniques in the pharmaceutical or biotechnology industry.
  • Experience independently generating trial designs, writing protocols and informed consent forms, constructing appropriate case report forms, and coordinating cross-functionally.
  • In-depth therapeutic-area expertise and relevant clinical-trial experience, or a clear ability to adapt transferable skills.
  • Strong knowledge of the medical aspects of Good Clinical Practice, International Conference on Harmonisation guidelines, Food and Drug Administration requirements, European Medicines Agency requirements, and other relevant guidelines and regulations.
  • Proven ability to work effectively and efficiently within cross-functional drug-development teams and integrate multiple perspectives into the clinical development plan.
  • Experience authoring regulatory briefing packages, writing responses to health-authority questions, and contributing to strategic approaches and cross-functional coordination for regulatory activities and interactions.
  • Demonstrated success driving cross-functional, study-level strategy, including study design, feasibility support, timeline and budget projections, protocol amendment requirements, and relevant discussions at internal decision-making bodies or governance forums.
  • Proven ability to build and maintain relationships with external key opinion leaders and contribute to advisory boards, individual engagements, and steering committees.
  • Experience engaging investigators to optimize clinical-trial conduct, including presenting at investigator meetings.
  • Strong teamwork orientation and leadership, communication, and interpersonal skills, with the ability to inspire, motivate, and mentor across a diverse team.
  • Experience mentoring other clinical scientists and experience or clear potential to be an effective line manager.
  • Expertise building and maintaining relationships with internal and external stakeholders.
  • Strategic-thinking and analytical skills sufficient to make data-driven decisions, recognize trade-offs, and determine priorities and goals in a fast-paced environment.
  • Strong written communication and business-presentation skills.
  • Adaptability and flexibility.
  • Ability to anticipate needs and assess and manage business and organizational risks.
Responsibilities
  • Lead the clinical science aspects of the clinical development strategy and clinical documentation.
  • Represent the clinical development plan on appropriate teams, sub-teams, and forums.
  • Oversee training of study-site personnel.
  • Act as the primary point of contact for program-level questions and inquiries regarding the clinical development plan.
  • Oversee medical and safety data reviews and study reporting.
  • Perform responsibilities independently with clear, self-directed leadership on complex and high-priority strategic studies.
  • Align efforts cross-functionally with scientific, regulatory, and commercial objectives while executing the clinical development plan.
  • Lead, mentor, and contribute to a high-performing cross-functional team of clinical development professionals.
  • Oversee clinical-trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
  • Establish and maintain relationships with clinical investigators, regulatory agencies, and key stakeholders.
  • Gather, analyze, and interpret clinical data to provide strategic insights for critical decisions and program development.
  • Manage clinical-development timelines, resource allocation, and milestone achievement.
  • Monitor scientific advancements and regulatory trends in clinical development.
  • Potentially manage multiple direct reports.
Desired Qualifications
  • Significant contributions to clinical development plan conception, conduct, and delivery, including successful alignment with scientific governance.
  • Experience enhancing or developing core and sub-team processes, structures, systems, tools, and other resources in the pharmaceutical or biotechnology industry.
  • Experience leading clinical development contributions to major regulatory submissions, including supplemental new drug applications, supplemental biologics license applications, pediatric investigation plans, pediatric study plans, label negotiations, Breakthrough Therapy Designation, and Accelerated Review.
  • Proven ability to present clinical development aspects of programs to major health authorities such as the Food and Drug Administration and European Medicines Agency by teleconference or in person.
  • Experience leading health-authority interactions.
  • Proven ability to establish clinical development strategy for Clinical Trial Application or Ethics Committee submissions and responses to health-authority questions.
  • Experience collaborating on enterprise-level strategic initiatives with internal and external partners and stakeholders, including clinical investigators, clinicians, scientists, key opinion leaders, development, research, business development, commercial, and legal groups, with demonstrable outcomes that enhance strategic goals.
  • Influential and inspiring leadership with the ability to bring teams and individuals along.
  • Courage and conviction in past positions and responsibilities.
  • Conflict-resolution skills.

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted daraxonrasib NDA on July 22, 2026 for previously treated metastatic pancreatic cancer.
  • BeOne will fund a global Phase 3 study and pay milestones plus Asian royalties.
  • Cash and marketable securities reached $3.9 billion on June 30, 2026, extending runway.

What critics are saying

  • FDA acceptance on July 22, 2026 starts review; rejection kills the lead thesis.
  • Commercial launch needs payer adoption against cheap chemotherapy and entrenched oncology incumbents by 2027.
  • A failed RASolve 301 readout or safety signal would crater the entire RAS(ON) platform.

What makes Revolution Medicines unique

  • Daraxonrasib posted 13.2-month median OS in RASolute 302 on April 13, 2026.
  • Revolution Medicines targets active RAS(ON), spanning KRAS G12X, G12D, and G12V biology.
  • August 10, 2026 BeOne deal validates a portfolio, not just one pancreatic asset.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-4%
Ticker Report
Aug 16th, 2026
Centric Wealth Management Makes New $505,000 Investment in Revolution Medicines, Inc. $RVMD

Centric Wealth Management purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) during the second quarter, HoldingsChannel.com reports. The fund purchased 3,416 shares of the company’s stock, valued at approximately $505,000. Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. […]

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

nuaxia
Aug 12th, 2026
BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal.

BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal. The collaboration pairs BeOne's oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets. BeOne Medicines and Revolution Medicines have entered a multi-part oncology collaboration covering combination studies involving BeOne pipeline assets and four clinical-stage RAS(ON) inhibitors - daraxonrasib, zoldonrasib, elironrasib and RMC-5127 - alongside exclusive regional development and commercialisation rights in selected Asian markets. The agreement combines BeOne's development and regional commercial infrastructure with Revolution Medicines' RAS-targeted portfolio and creates opportunities to evaluate new combination approaches for patients with RAS-addicted cancers. | Field | Content | | Alert Type | Deal | | Companies | BeOne Medicines; Revolution Medicines | | Deal Type | Clinical development collaboration and regional licensing agreement | | Asset or Company | Revolution Medicines' daraxonrasib, zoldonrasib, elironrasib and RMC-5127; BeOne's BGB-58067 and BG-T187 among the planned combination assets | | Therapy Area(s) | Oncology; RAS-addicted cancers | | Technology or Modality | RAS(ON) inhibitors; PRMT5 inhibitor; trispecific EGFR x MET x MET antibody | | Deal Value | Financial terms were not fully disclosed. Revolution Medicines is eligible to receive development and sales milestone payments plus tiered royalties on net sales from the licensed Asian territories. | | Development Stage | Clinical stage; the four Revolution Medicines RAS(ON) inhibitors are in clinical development, with BeOne also responsible for funding and conducting a global registrational Phase III trial for one of the assets. | | Geography | Global clinical collaboration plus selected Asian markets for licensed rights. Revolution Medicines retains rights outside the licensed territories, including Japan and South Korea. | | What Happened | On 11 August 2026, BeOne Medicines and Revolution Medicines announced a multi-part collaboration focused on RAS-addicted cancers. The companies plan to evaluate combinations of BeOne pipeline assets, including the MTA-cooperative PRMT5 inhibitor BGB-58067 and trispecific EGFR x MET x MET antibody BG-T187, with Revolution Medicines' four clinical-stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib and RMC-5127. Separately, Revolution Medicines granted BeOne exclusive development and commercialisation, or commercialisation-only rights depending on the territory, for the four RAS(ON) inhibitors in selected Asian markets. BeOne will also fund and conduct a global registrational Phase III trial for one of the Revolution Medicines assets. | | Why It Matters | The agreement extends the development opportunities for Revolution Medicines' RAS(ON) portfolio beyond monotherapy by testing combinations with mechanistically different oncology assets from BeOne. It also gives BeOne access to four clinical-stage RAS-targeted programmes across selected Asian markets, allowing the company to use its development and commercial infrastructure to support their regional development and potential launches. | | Supporting Context | RAS alterations are important oncogenic drivers across multiple tumour types and have historically been difficult to target therapeutically. Revolution Medicines is developing RAS(ON) inhibitors designed to target active RAS proteins, while BeOne has a broader oncology pipeline containing potential combination partners with different mechanisms of action. | | Strategic Rationale | Revolution Medicines gains access to BeOne's oncology assets for combination studies while retaining development and commercial rights to its RAS(ON) programmes outside the licensed Asian territories. BeOne gains regional rights to four clinical-stage RAS inhibitors and the opportunity to evaluate its existing oncology pipeline in combinations that could potentially broaden the therapeutic application of both companies' programmes. | | Potential Impact | Successful studies could establish additional combination strategies for RAS-addicted cancers and broaden the development opportunities for both companies' oncology pipelines. Any clinical or commercial impact will depend on trial results and subsequent regulatory approvals. | | Key Takeaway | The collaboration combines BeOne's oncology pipeline and Asian development infrastructure with four Revolution Medicines RAS(ON) inhibitors, creating both new combination programmes and a regional commercial partnership. | | What to Watch | Initiation and results of the planned combination studies, identification of the RAS(ON) inhibitor selected for BeOne's global registrational Phase III trial and subsequent development and regulatory progress across the licensed Asian territories. | | Primary Source | BeOne Medicines / Revolution Medicines collaboration announcement | | Relevant Date | 11 August 2026 | Discover how nuaxia can support your next medical education initiative:

The Montreal Gazette
Aug 10th, 2026
BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration.

BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration. Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets SAN CARLOS, Calif. & REDWOOD CITY, Calif. - BeOne Medicines Ltd. (Nasdaq: ONC; HKEX:...

Associated Press
Aug 5th, 2026
Revolution Medicines files daraxonrasib NDA for pancreatic cancer, raises $2.2B

Revolution Medicines announced second quarter 2026 financial results, reporting cash and marketable securities of $3.9 billion as of 30 June. The company completed concurrent public offerings totalling $2.2 billion in gross proceeds and received $250 million from Royalty Pharma. The FDA accepted the company's new drug application for daraxonrasib to treat previously treated metastatic pancreatic cancer. Over 2,000 patients have received the drug through an expanded access programme since May. The FDA also granted breakthrough therapy designation for daraxonrasib in certain non-small cell lung cancer patients. Research and development expenses rose to $394.9 million from $224.1 million year-over-year, whilst general and administrative expenses increased to $110.2 million from $40.6 million. Net loss totalled $644.4 million, compared to $247.8 million in the prior year quarter.